Soligenix shares fall 7.06% after-hours following a corporate presentation on rare disease treatment.

Soligenix, Inc. dropped 7.06% in after-hours trading. The company recently held a corporate presentation titled "Rising to the Challenges of Rare Disease Treatment," highlighting its focus on developing products for orphan diseases and areas of unmet medical need in oncology and inflammation, as well as vaccines and therapeutics for military and civilian applications.